Logo image of NLTX

NEOLEUKIN THERAPEUTICS INC (NLTX) Stock Fundamental Analysis

NASDAQ:NLTX - Nasdaq - US64049K2033 - Common Stock - Currency: USD

3.49  +0.05 (+1.45%)

After market: 3.42 -0.07 (-2.01%)

Fundamental Rating

3

Taking everything into account, NLTX scores 3 out of 10 in our fundamental rating. NLTX was compared to 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NLTX as it has an excellent financial health rating, but there are worries on the profitability. NLTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NLTX had negative earnings in the past year.
In the past year NLTX has reported a negative cash flow from operations.
NLTX had negative earnings in each of the past 5 years.
NLTX had a negative operating cash flow in each of the past 5 years.
NLTX Yearly Net Income VS EBIT VS OCF VS FCFNLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

NLTX has a Return On Assets of -38.25%. This is in the better half of the industry: NLTX outperforms 63.11% of its industry peers.
With a decent Return On Equity value of -45.57%, NLTX is doing good in the industry, outperforming 69.12% of the companies in the same industry.
Industry RankSector Rank
ROA -38.25%
ROE -45.57%
ROIC N/A
ROA(3y)-34.21%
ROA(5y)-38.12%
ROE(3y)-40.31%
ROE(5y)-42.67%
ROIC(3y)N/A
ROIC(5y)N/A
NLTX Yearly ROA, ROE, ROICNLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

NLTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLTX Yearly Profit, Operating, Gross MarginsNLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

NLTX has about the same amout of shares outstanding than it did 1 year ago.
NLTX has a worse debt/assets ratio than last year.
NLTX Yearly Shares OutstandingNLTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
NLTX Yearly Total Debt VS Total AssetsNLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -6.37, we must say that NLTX is in the distress zone and has some risk of bankruptcy.
NLTX has a worse Altman-Z score (-6.37) than 71.29% of its industry peers.
NLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.37
ROIC/WACCN/A
WACCN/A
NLTX Yearly LT Debt VS Equity VS FCFNLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

NLTX has a Current Ratio of 15.37. This indicates that NLTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 15.37, NLTX belongs to the top of the industry, outperforming 89.32% of the companies in the same industry.
A Quick Ratio of 15.37 indicates that NLTX has no problem at all paying its short term obligations.
NLTX has a better Quick ratio (15.37) than 89.48% of its industry peers.
Industry RankSector Rank
Current Ratio 15.37
Quick Ratio 15.37
NLTX Yearly Current Assets VS Current LiabilitesNLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

NLTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.78%.
EPS 1Y (TTM)-136.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NLTX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.72%
EPS Next 2Y40.24%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLTX Yearly Revenue VS EstimatesNLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 200M 400M 600M 800M
NLTX Yearly EPS VS EstimatesNLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NLTX. In the last year negative earnings were reported.
Also next year NLTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLTX Price Earnings VS Forward Price EarningsNLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLTX Per share dataNLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as NLTX's earnings are expected to grow with 23.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.24%
EPS Next 3Y23.36%

More info and screens

0

5. Dividend

5.1 Amount

NLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEOLEUKIN THERAPEUTICS INC

NASDAQ:NLTX (12/18/2023, 8:15:14 PM)

After market: 3.42 -0.07 (-2.01%)

3.49

+0.05 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-18 2024-03-18/amc
Inst Owners0.15%
Inst Owner Change0%
Ins Owners41.27%
Ins Owner Change0%
Market Cap30.71M
Analysts43.33
Price Target1.53 (-56.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-5.2
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-3.74
FCFYN/A
OCF(TTM)-3.67
OCFYN/A
SpS0
BVpS8.55
TBVpS8.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.25%
ROE -45.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.21%
ROA(5y)-38.12%
ROE(3y)-40.31%
ROE(5y)-42.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.37
Quick Ratio 15.37
Altman-Z -6.37
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.83%
EPS Next Y93.72%
EPS Next 2Y40.24%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.63%
OCF growth 3YN/A
OCF growth 5YN/A